1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. DERMATA THERAPEUTICS INC
Dermata Therapeutics Inc
XNAS: DRMA
Download real time
1.110.01(0.91%)
81.09% Fall from 52W High
14,095
XNAS Volume

XNAS 05 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Dermata Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Dermata Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue Dermata Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit Dermata Therapeutics Inc Jun-2026 Quarterly Net Profit is $-3 Million which is growth of -74.4% YoY.

Dermata Therapeutics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
31.91.91.81.82.33.23.22.93.22.21.81.7
Operating Profit
-3-1.9-1.9-1.8-1.8-2.3-3.2-3.2-2.9-3.2-2.2-1.8-1.7
⌄
0.10.100.10.100.10.10.10.10.10.10
Profit Before Tax
-3-1.9-1.9-1.7-1.7-2.3-3.2-3.2-2.8-3.1-2.1-1.7-1.7
Tax
-------------
⌄
-3-1.9-1.9-1.7-1.7-2.3-3.2-3.2-2.8-3.1-2.1-1.7-1.7
Diluted NI Avail to Com Stockholders Ann.
-3-1.9-1.9-1.7-1.7-2.3-3.2-3.2-2.8-3.1-2.1-1.7-1.7
Basic EPS
-0.7-0.5-1.5-1.7-1.7-4.5-12.5-20.4-41.8-70.5-81.4-81-94.5
Diluted EPS After ExtraOrdinary
-0.7-0.5-1.5-1.7-1.7-4.5-12.5-20.4-41.8-70.5-81.4-81-94.5
Number Of Shares End
43.91.1110.50.30.20.10000
Net Income Continuing Discontinued Operations
-3-1.9-1.9-1.7-1.7-2.3-3.2-3.2-2.8-3.1-2.1-1.7-1.7
Normalized Income
-3-1.9-1.9-1.7-1.7-2.3-3.2-3.2-2.8-3.1-2.1-1.7-1.7
Interest Income
0.10.100.10.100.10.10.10.10.10.10
Interest
-------------
Net Interest Income
0.10.100.10.100.10.10.10.10.10.10
EBIT
-3-1.9-1.9-1.8-1.8-2.3-3.2-3.2-2.9-3.2-2.2-1.8-1.7
EBITDA
-3-1.9-1.9-1.8-1.8-2.3-3.2-3.2-2.9-3.2-2.2-1.8-1.7
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
-------------
Profit From Continuing Operations
-3-1.9-1.9-1.7-1.7-2.3-3.2-3.2-2.8-3.1-2.1-1.7-1.7
Normalized EBITDA
-3-1.9-1.9-1.8-1.8-2.3-3.2-3.2-2.9-3.2-2.2-1.8-1.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Dermata Therapeutics Inc competitor comparison and performance snapshot within industry

Dermata Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEUTRAL

    Annual Revenue Dermata Therapeutics Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Annual Net Profit Dermata Therapeutics Inc Annual Net Profit is $-8 Million which is growth of 38.5% YoY.

Dermata Therapeutics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
⌄
-
-
 
Cost Of Rev. Ann.
-
-
 -------
Gross Profit Ann.
-
-
 -------
Operating Exp. Ann.
-7%
19.5%
8.67.812.589.77.93.24.5
Operating Profit Ann.
-
-
-8.6-7.8-12.5-8-9.7-7.9-3.2-4.5
⌄
26%
-
0.20.20.20.30.1-0.1-0.2-0.3
Other Exp. Ann.
-
-
 -----0.1-
PBT Ann.
-
-
-8.4-7.6-12.3-7.8-9.6-7.9-3.2-4.7
Tax Ann.
-
-
 -------
⌄
-
-
-8.4-7.6-12.3-7.8-9.6-10.5-3.2-4.7
Diluted NI Avail to Com Stockholders Ann.
-
-
-8.4-7.6-12.3-7.8-9.6-10.5-3.2-4.7
EPS Ann.
-
-
 -8.2-80.3-400.5-2,088-5,832-933.6-1,360.6
Diluted EPS Ann.
-
-
 -8.2-80.3-400.5-2,088-5,832-933.6-1,360.6
Number Of Shares End
-
-
 1.10.300-
Total Exp. Ann.
-7%
19.5%
 7.812.589.77.93.24.5
Net Income Continuing Discontinued Operations Ann.
-
-
-8.4-7.6-12.3-7.8-9.6-7.9-3.2-4.7
Normalized Income Ann.
-
-
-8.4-7.6-12.3-7.8-9.6-7.9-3.4-4.7
Interest Income Ann.
-
-
0.20.20.20.3----
Interest Ann.
-
-
 ----0.10.20.3
EBITDA Ann.
-
-
-8.6-7.8-12.5-8-9.7-7.9-3-4.5
Reconciled Cost Of Rev. Ann.
-
-
 -------
Reconciled Depr. Ann.
-
-
 ----
Profit From Continuing Operations Ann.
-
-
-8.4-7.6-12.3-7.8-9.6-7.9-3.2-4.7
Normalized EBITDA Ann.
-
-
-8.6-7.8-12.5-8-9.7-7.9-3.2-4.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
-37.6%
2Y CAGR
-1.3%
3Y CAGR
-7%
5Y CAGR
19.5%

Dermata Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Dermata Therapeutics Inc Dec-2025 Total Shareholders Fund is $6 Million which is growth of 298.7% YoY.

  • POSITIVE

    Total Assets Dermata Therapeutics Inc Dec-2025 Total Assets is $8 Million which is growth of 122.5% YoY.

Dermata Therapeutics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
⌄
4.6%
67.5%
7.93.586.911.60.62.1
⌄
21.1%
-15.9%
1.621.60.91.53.82.3
⌄
1.1%
-
6.21.66.4610.1-3.2-0.2
Total Capitalization Ann.
1.1%
-
6.21.66.4610.1-3.20.3
Tangible Assets Ann.
1.1%
-
6.21.66.4610.1
Working Capital Ann.
1.1%
-
6.21.66.4610.1-3.20.3
Invested Capital Ann.
1.1%
73%
6.21.66.4610.10.41.1
Tangible Book Value Ann.
1.1%
-
6.21.66.4610.1-3.2-0.2
Borrowings Ann.
-
-
-----3.61.3
Net Debt Ann.
-
-
-----3-
Share Issued Ann.
-
-
2.70.300
Number Of Shares End
-
-
1.10.300-
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
125.7%
2Y CAGR
-0.6%
3Y CAGR
4.6%
5Y CAGR
67.5%
Total Current Liabilities Ann.
1Y CHG
-20%
3Y CAGR
21.1%
5Y CAGR
-15.9%
Total ShareHolders Funds Ann.
1Y CHG
287.5%
2Y CAGR
-1.6%
3Y CAGR
1.1%

Dermata Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Dermata Therapeutics Inc Book Value Per Share is $1 which is growth of -91.5% YoY.

  • NEUTRAL

    ROE Dermata Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Dermata Therapeutics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
RoA Ann. %
-
-
--213.46%-104.46%-103.52%-171.14%-242.32%-228.55%
ROE Ann. %
-
-
--310.44%-125.96%-119.18%-302.05%--
ROIC %
-
-
--101.6-34.8-24.8-9.1--
OPM Ann. %
-
-
-------
Inventory Turnover Ratio Ann.
-
-
-------
Asset Turnover Ann. %
-
-
-------
Working Capital Turnover Ann.
-
-
Quick Ratio Ann.
-
-
-1.64.66.87.10.11.2
Current Ratio Ann.
-
-
-1.84.97.57.70.21.2
Interest Coverage Ratio Ann.
-
-
-----172.3-15.4-17.8
LT Debt To Equity Ann.
-
-
-------
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Dermata Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Dermata Therapeutics Inc Cash From Operating Activity is $-8 Million which is growth of 30.5% YoY.

  • NEUTRAL

    Net Cash Flow Dermata Therapeutics Inc Net Cash Flow is $0 Million which is growth of 0% YoY.

Dermata Therapeutics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
⌄
-
-
-7.8-11.2-6.4-8.8-5.7-4-3.9
⌄
-
-
-------
⌄
41.2%
36%
12.16.97.64.3162.64.7
Cash Plus Cash Eqv. End Of Year Ann.
6.6%
71.9%
7.53.27.46.210.80.52
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
4.4-4.31.2-4.610.3-1.50.8
Cash Plus Cash Eqv. Begin Of Year Ann.
-33.3%
9.9%
3.27.46.210.80.521.2
Income Tax Paid Supplemental Data Ann.
-
-
Interest Paid Supplemental Data Ann.
-
-
---0.10.1
Capex Ann.
-
-
-------
Issuance Of Capital Stock Ann.
41.6%
109.8%
12.26.97.64.3160.35.4
Issuance Of Debt Ann.
-
-
---1.63.10.2
Repayment Of Debt Ann.
-
-
----0.6-0.8-0.8
Repurchase Of Capital Stock Ann.
-
-
-1--
Free Cash Flow Ann.
-
-
-7.8-11.2-6.4-8.8-5.7-4-3.9
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
75.4%
2Y CAGR
26.2%
3Y CAGR
41.2%
5Y CAGR
36%
×